Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold” by Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have been given an average recommendation of “Hold” by the nineteen ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $109.6154.

A number of research firms have commented on ZTS. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Barclays lowered their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. BNP Paribas Exane reduced their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Piper Sandler decreased their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Finally, Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th.

Zoetis Trading Down 0.2%

Shares of NYSE:ZTS opened at $73.64 on Wednesday. Zoetis has a 52 week low of $71.45 and a 52 week high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.43 billion, a PE ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.73. The company’s 50 day moving average is $76.30 and its two-hundred day moving average is $98.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 34.93%.

Institutional Investors Weigh In On Zoetis

A number of large investors have recently added to or reduced their stakes in the business. University of Texas Texas AM Investment Management Co. purchased a new position in Zoetis in the 2nd quarter valued at about $25,000. Dunhill Financial LLC lifted its stake in shares of Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after buying an additional 296 shares during the period. Prosperity Bancshares Inc acquired a new stake in Zoetis during the fourth quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the 1st quarter valued at $28,000. Finally, Root Financial Partners LLC lifted its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.